At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ZBIO Zenas BioPharma Inc.
Trading 02-02 12:23:17 EST
18.52
+0.15
+0.82%
High18.57Low17.60Vol306.98K
Open18.33D1 Closing18.37Amplitude5.25%
Mkt Cap994.14MTradable Cap390.25MTotal Shares53.68M
T/O5.57MT/O Rate1.46%Tradable Shares21.07M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Zenas BioPharma Grants Stock Options to New Employee Under Inducement Plan
Reuters  ·  01-17
Zenas BioPharma Grants Stock Options to New Employee Under Inducement Plan
Zenas Biopharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
THOMSON REUTERS  ·  01-17
Zenas Biopharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire  ·  01-17
Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Zenas Biopharma Unveils Pipeline Strategy Targeting Autoimmune and Multiple Sclerosis Markets
Reuters  ·  01-12
Zenas Biopharma Unveils Pipeline Strategy Targeting Autoimmune and Multiple Sclerosis Markets
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
Benzinga_recent_news  ·  01-10
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
Zenas Biopharma CEO Leon O. Moulder Jr. Acquires Common Shares
Reuters  ·  01-10
Zenas Biopharma CEO Leon O. Moulder Jr. Acquires Common Shares
Morgan Stanley Downgrades Zenas BioPharma to Equalweight From Overweight, Adjusts Price Target to $19 From $37
MT Newswires Live  ·  01-06
Morgan Stanley Downgrades Zenas BioPharma to Equalweight From Overweight, Adjusts Price Target to $19 From $37
Why Zenas BioPharma's Selloff Was Structurally Inevitable
Benzinga_recent_news  ·  01-06
Why Zenas BioPharma's Selloff Was Structurally Inevitable
A Look At Zenas BioPharma (ZBIO) Valuation After Recent Volatility And Premium Price To Book Ratio
Simply Wall St.  ·  01-06
A Look At Zenas BioPharma (ZBIO) Valuation After Recent Volatility And Premium Price To Book Ratio
Top Midday Decliners
MT Newswires Live  ·  01-06
Top Midday Decliners
Zenas Biopharma Shares Hit More Than Four-Month Low After Late-Stage Data for Immune Disorder Drug, Last Down 55%
THOMSON REUTERS  ·  01-05
Zenas Biopharma Shares Hit More Than Four-Month Low After Late-Stage Data for Immune Disorder Drug, Last Down 55%
Zenas BioPharma's immune disorder drug meets main goal in late-stage trial
Reuters  ·  01-05
Zenas BioPharma's immune disorder drug meets main goal in late-stage trial
Top Premarket Decliners
MT Newswires Live  ·  01-05
Top Premarket Decliners
Zenas Biopharma Reports Positive Phase 3 Results for Obexelimab in IgG4-Related Disease
Reuters  ·  01-05
Zenas Biopharma Reports Positive Phase 3 Results for Obexelimab in IgG4-Related Disease
Zenas Biopharma Inc - Obexelimab Meets All Four Secondary Efficacy Endpoints
THOMSON REUTERS  ·  01-05
Zenas Biopharma Inc - Obexelimab Meets All Four Secondary Efficacy Endpoints
Zenas Biopharma Announces Positive Results From Phase 3 Indigo Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (Igg4-Rd)
THOMSON REUTERS  ·  01-05
Zenas Biopharma Announces Positive Results From Phase 3 Indigo Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (Igg4-Rd)
Zenas Biopharma Inc - Plans Bla Submission to FDA in Q2 2026
THOMSON REUTERS  ·  01-05
Zenas Biopharma Inc - Plans Bla Submission to FDA in Q2 2026
Zenas Biopharma Inc - Obexelimab Achieves 56% Reduction in Igg4-Rd Flare Risk
THOMSON REUTERS  ·  01-05
Zenas Biopharma Inc - Obexelimab Achieves 56% Reduction in Igg4-Rd Flare Risk
Zenas Biopharma Inc: Obexelimab Was Well Tolerated and No New Safety Signals Were Observed
THOMSON REUTERS  ·  01-05
Zenas Biopharma Inc: Obexelimab Was Well Tolerated and No New Safety Signals Were Observed
Zenas Biopharma Inc: Anticipates Submitting a Maa to Ema in H2 2026
THOMSON REUTERS  ·  01-05
Zenas Biopharma Inc: Anticipates Submitting a Maa to Ema in H2 2026

Introduction

Company Name.
Zenas BioPharma Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Issue price:
--